Cyclerion Therapeutics (CYCN) Competitors $2.47 -0.10 (-3.89%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCN vs. COEP, MRNS, EQ, GDTC, CALC, LGVN, VYNE, QTTB, DRRX, and SNYRShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Coeptis Therapeutics (COEP), Marinus Pharmaceuticals (MRNS), Equillium (EQ), CytoMed Therapeutics (GDTC), CalciMedica (CALC), Longeveron (LGVN), VYNE Therapeutics (VYNE), Q32 Bio (QTTB), DURECT (DRRX), and Synergy CHC Corp. (Uplisting) (SNYR). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Coeptis Therapeutics Marinus Pharmaceuticals Equillium CytoMed Therapeutics CalciMedica Longeveron VYNE Therapeutics Q32 Bio DURECT Synergy CHC Corp. (Uplisting) Cyclerion Therapeutics (NASDAQ:CYCN) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk. Is CYCN or COEP more profitable? Cyclerion Therapeutics' return on equity of -55.32% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cyclerion TherapeuticsN/A -55.32% -48.35% Coeptis Therapeutics N/A -1,094.50%-219.97% Do analysts prefer CYCN or COEP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals believe in CYCN or COEP? 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 36.1% of Cyclerion Therapeutics shares are owned by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, CYCN or COEP? Cyclerion Therapeutics has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.77, indicating that its share price is 177% less volatile than the S&P 500. Does the media prefer CYCN or COEP? In the previous week, Cyclerion Therapeutics had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 2 mentions for Cyclerion Therapeutics and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.87 beat Cyclerion Therapeutics' score of 1.44 indicating that Coeptis Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Cyclerion Therapeutics Positive Coeptis Therapeutics Very Positive Which has preferable earnings & valuation, CYCN or COEP? Cyclerion Therapeutics has higher revenue and earnings than Coeptis Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclerion Therapeutics$2M3.35-$5.26M-$1.22-2.02Coeptis TherapeuticsN/AN/A-$21.27M-$5.80-1.59 Does the MarketBeat Community prefer CYCN or COEP? Cyclerion Therapeutics received 29 more outperform votes than Coeptis Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Coeptis Therapeutics an outperform vote while only 58.62% of users gave Cyclerion Therapeutics an outperform vote. CompanyUnderperformOutperformCyclerion TherapeuticsOutperform Votes3458.62% Underperform Votes2441.38% Coeptis TherapeuticsOutperform Votes583.33% Underperform Votes116.67% SummaryCyclerion Therapeutics beats Coeptis Therapeutics on 10 of the 14 factors compared between the two stocks. Remove Ads Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.70M$6.87B$5.61B$7.68BDividend YieldN/A2.79%5.33%4.02%P/E Ratio-2.037.3523.5018.55Price / Sales3.35208.36376.0088.66Price / CashN/A65.6738.1734.64Price / Book0.536.256.814.11Net Income-$5.26M$142.34M$3.20B$247.18M7 Day Performance-12.41%-8.43%-5.42%-4.05%1 Month Performance-7.49%-9.99%-0.12%-6.41%1 Year Performance-22.81%-12.60%7.61%-2.08% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics2.3063 of 5 stars$2.47-3.9%N/A-19.7%$6.70M$2M-2.0330Short Interest ↓Positive NewsCOEPCoeptis Therapeutics0.789 of 5 stars$9.41-0.9%N/A+57.7%$30.51MN/A-1.622Positive NewsMRNSMarinus Pharmaceuticals2.3123 of 5 stars$0.55-0.2%$4.79+771.6%-93.9%$30.32M$30.99M-0.22110EQEquillium2.7458 of 5 stars$0.82+6.1%$5.00+509.8%-82.5%$29.05M$45.91M-5.8640Earnings ReportAnalyst DowngradeAnalyst RevisionNews CoverageGDTCCytoMed Therapeutics2.4649 of 5 stars$2.64+1.1%$5.00+89.4%+3.2%$28.88MN/A0.00N/AShort Interest ↓Positive NewsCALCCalciMedica2.4919 of 5 stars$2.08+3.5%$18.00+765.4%-52.2%$28.04MN/A-1.9330Earnings ReportGap UpLGVNLongeveron2.1466 of 5 stars$1.86+0.5%$8.67+365.9%-51.4%$27.77M$2.39M-0.3020Short Interest ↑VYNEVYNE Therapeutics2.8813 of 5 stars$1.75+1.7%$6.88+292.9%-44.6%$26.62M$501,000.00-2.0330Short Interest ↑High Trading VolumeQTTBQ32 Bio2.5956 of 5 stars$2.18+5.3%$24.71+1,033.7%-90.0%$26.59M$-6,651,000.00-0.1539Positive NewsDRRXDURECT2.8322 of 5 stars$0.85flat$5.00+488.9%-33.9%$26.36M$8.59M-1.3980Earnings ReportSNYRSynergy CHC Corp. (Uplisting)3.7098 of 5 stars$3.02-6.8%$10.00+231.1%N/A$26.29M$26.01M0.0040Earnings ReportPositive NewsGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies COEP Competitors MRNS Competitors EQ Competitors GDTC Competitors CALC Competitors LGVN Competitors VYNE Competitors QTTB Competitors DRRX Competitors SNYR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCN) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
